Introduction {#s1}
============

Arsenic exposure from naturally contaminated drinking water is a global public health concern that affects $> 200\text{ \ million}$ people worldwide ([@c58]), and $\sim 56\text{ \ million}$ in Bangladesh ([@c27]). Prior to remediation efforts, $\sim 95\%$ of the drinking water wells in Bangladesh contained water with inorganic arsenic concentrations above $10\;\mu g/L$, the World Health Organization (WHO) recommended maximum level of exposure ([@c3]; [@c5]; [@c82]). Inorganic arsenic is classified as a group I carcinogen by the International Agency for Research on Cancer, and long-term exposure is associated with risk for nonmelanoma skin ([@c40]), lung ([@c45]), and bladder cancer ([@c29]; [@c45]) as well as arsenical skin lesions (a hallmark of chronic arsenic exposure). Chronic environmental arsenic exposure also increases the risk of other chronic diseases, including cardiovascular diseases ([@c57]; [@c59]) and respiratory disease ([@c72]) and overall mortality among Bangladeshi adults ([@c9]).

Arsenic is not considered to be directly genotoxic, and potential mechanisms of arsenic toxicity include induction of oxidative stress and inflammation, inhibition of DNA repair, and epigenetic dysregulation, including alteration of DNA methylation. DNA methylation is characterized by the addition of a methyl group to a cytosine nucleotide, frequently located within CpG sites in the genome. DNA methylation (and the underlying chromatin state it represents) provides an additional level of transcriptional regulation and has an important role in maintaining genomic stability. Exposure to environmental toxicants, like arsenic, can induce changes in both global and gene-specific DNA methylation ([@c22]; [@c53]). Some potential mechanisms by which arsenic could disrupt DNA methylation include interaction with methylation or chromatin maintenance machinery, depletion of cofactors involved in DNA methylation synthesis, interaction with transcription factor binding sites (TFBS), and alteration of the inflammatory and oxidative environment of the cell ([@c12]; [@c69]). Arsenic-induced alterations of DNA methylation may be an important component in the mechanism of arsenic toxicity and carcinogenesis.

While several studies have examined prenatal arsenic exposure and genome-wide DNA methylation ([@c16], [@c17]; [@c32]; [@c42]; [@c44]; [@c71]), only four studies have examined arsenic exposure and genome-wide DNA methylation in adults ([@c4]; [@c8]; [@c50]; [@c75]). Argos et al. identified four urinary arsenic--associated CpGs and three blood arsenic--associated CpGs (Bonferroni threshold of $p < 10^{- 7}$) in Bangladeshi adults ($n = 400$), with a wide range of environmental arsenic exposure and diagnosed with skin lesions ([@c8]). Liu et al. identified 22 differentially methylated CpGs ($p < 10^{- 4}$) in adults ($n = 46$) from the United States with low arsenic exposure compared with adults in Bangladesh ([@c50]). Ameer et al. identified six urinary arsenic--associated CpGs \[$\text{false\ discovery\ rate\  }\left( \text{FDR} \right) < 0.05$\] among Andean women from Argentina ($n = 93$) with a wide range of environmental exposure, similar to Bangladesh ([@c4]). Seow et al. conducted a pilot study comparing genome-wide DNA methylation between 10 arsenical skin lesions cases and 10 lesion-free controls from Bangladesh, but no significant associations with methylation were observed ([@c75]). These prior studies differed with respect to study population, sample size, exposure assessment and level, disease status, and statistical approaches, likely contributing to the variability in CpGs identified and patterns of genome-wide methylation observed ([@c7]). Prior studies used the Illumina $450\; K$ array, while the newer Illumina InfiniumMethylationEPIC (EPIC) array measures methylation at approximately 850,000 CpGs, including $> 90\%$ of the CpGs on the $450\; K$ array as well as substantial coverage of CpGs in enhancer regions and CpG shores ([@c66]). By including these additional sites, the EPIC array enables evaluation of methylation within distal regulatory regions of the genome that may be more susceptible to environmental exposures, like arsenic, since methylation at enhancers is more variable and dynamic and not as well preserved ([@c38]).

In this study, we assess the association between exposure to arsenic measured in urine (prior to arsenic mitigation efforts) and genome-wide DNA methylation assessed using the EPIC array in 396 adults from the Health Effects of Arsenic Longitudinal Study (HEALS). HEALS is a population-based cohort of arsenic-exposed Bangladeshi adults established to assess the health effects associated with consumption of arsenic-contaminated water ([@c1]). We validate arsenic-associated CpGs by examining their association with arsenic concentration in drinking water and replicate observed associations in an independent cohort of 400 Bangladeshi adults. We then conduct a meta-analysis of both cohorts to identify additional putative arsenic-associated CpGs.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

HEALS was initiated to prospectively investigate the health outcomes associated with chronic arsenic exposure through consumption of groundwater in a sample of Bangladeshi adults with homogenous ethnic and sociocultural characteristics ($n = \sim 12,000$) and little to no genetic admixture in Araihazar, Bangladesh ([@c67]). This study has been described previously ([@c1]). HEALS participants were recruited between October 2000 and May 2002. Participants were sampled from married couples between ages 18--75 y who resided in study area for at least 5 y. Trained study physicians (blinded to arsenic exposure) conducted in-person interviews, clinical evaluations, and skin lesion assessment, and collected urine and blood samples using structured protocols ([@c2]). Participants in this epigenome-wide association study (EWAS) ($n = 396$) were randomly selected from the random subcohort recently included in a genome-wide association study ([@c67]).

Data from the Bangladesh Vitamin E and Selenium Trial (BEST) were used to replicate associations observed in HEALS. BEST is a $2 \times 2$ factorial randomized chemoprevention trial evaluating the effects of vitamin E and selenium dietary supplemental and skin cancer risk among individuals with arsenical skin lesions from rural central Bangladesh ([@c10]). BEST participants were recruited between August 2006 and August 2009 and were between 25--65 y old, resided in the study area, and had arsenical skin lesions. Arsenic exposure was assessed in urine, and whole blood was collected at baseline for all BEST participants. Genome-wide methylation was previously measured on the $450\; K$ array for 400 BEST participants, and the results were reported by Argos et al. ([@c8]). The study protocols were approved by the Institutional Review Boards of the University of Chicago, Columbia University, and the Bangladesh Medical Research Council. Informed consent was obtained from all participants.

Exposure Assessment {#s2.2}
-------------------

Arsenic was measured in both urine and water for each HEALS participant. At baseline, each participant identified the primary well used as their main source of drinking water. Spot urine samples were obtained from each participant at baseline. Arsenic in urine and water was measured using graphite furnace atomic absorption spectrometry (AAnalyst 600 spectrometer; Perkin Elmer) in a single laboratory (Trace Metal Core Laboratory at Columbia University), and the limit of detection for this method was $2\;\mu g/L$ and $5\;\mu g/L$ for urine and water, respectively ([@c61]). For arsenic in well water, any samples that were below the limit of detection were reanalyzed using inductively coupled plasma mass spectrometry with a detection limit of $0.1\;\mu g/L$ ([@c19]). Urine creatinine was measured by a colorimetric Sigma Diagnostics Kit (Sigma). Total urinary arsenic was divided by urine creatinine to obtain creatinine-adjusted urine arsenic ($\mu g/g$ creatinine).

DNA Methylation {#s2.3}
---------------

DNA was extracted from clotted blood using FlexiGene DNA Kit (Qiagen). We then bisulfite converted $500\text{ \ ng}$ of DNA using EZ-96 DNA Methylation™ Kit (Zymo Research). All samples were then prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Infinium MethylationEPIC array (Illumina). The EPIC array measured methylation at 866,895 CpGs. We removed CpGs with a detection $p > 0.01$ in one or more samples ($n = 26,629$) or missing methylation in $> 5\%$ of samples ($n = 85$). Cross-reactive CpGs were removed ($n = 41,920$), as well as CpGs annotating to a single-nucleotide polymorphism (SNP) or within a single base pair extension ($n = 7,791$) ([@c66]). We removed CpGs annotating to the X and Y chromosomes to avoid potential gender bias in methylation patterns as well as non-CpG and SNP probes on the array ($n = 19,278$). The total CpGs included in the analysis were 771,192.

One sample from HEALS was removed due to mismatched sex. After imputing beta values for missing CpG methylation using k-nearest neighbors method ($k = 10$) ([@c81]), the dataset was normalized using the beta mixture quantile (BMIQ) method. BMIQ is an assumption-free approach to adjust for type I/II probe bias ([@c79]). We applied the ComBat function in R to adjust for batch effect due to plate ([@c36]; [@c46]). This batch effect was removed after reviewing the principal components analysis of the batch-adjusted data. All processing of DNA methylation array data and analyses were conducted in R 3.4.1.

Association Analyses {#s2.4}
--------------------

All statistical analyses were performed using logit transformed beta values and *M*-values {log~2~\[beta/(1 − beta)\]}, unless noted. The range of beta values is 0 (0% methylated) to 1 (100% methylated), while *M*-values range from $- \infty$ to $\infty$. We selected covariates *a priori* and adjusted for age (continuous variable), sex, smoking status (categorized as never, former, and current smoker based on self-report), and body mass index (BMI) category \[categorized as normal (reference), underweight, overweight, obese, and unknown\]. We $\log_{2}\text{-transformed}$ urinary and water arsenic to reduce the influence of outlying values; arsenic exposure was also modeled as an untransformed continuous and an ordinal variable across integer-coded quartiles \[first ($< 113\;\mu g/g$), second ($114–201\;\mu g/g$), third ($202–350\text{ \ ug}/g$), fourth ($> 350\;\mu g/g$)\]. We applied surrogate variable analysis (SVA) to adjust for unknown biologic and technical effects ([@c47]; [@c46]). SVA has been demonstrated to perform stably ([@c54]) and optimally identify informative CpGs in genome-wide methylation studies ([@c41]), and it was chosen over a cell type--adjusted approach ([@c35]) as our primary analysis approach since it produced a lower genomic inflation factor. We estimated surrogate variables (SVs) using a permutation-based approach ([@c15]). For each CpG, we analyzed the association with arsenic using linear regression adjusting for SVs and covariates in limma in R ([@c70]) and computed the genomic inflation factor ($\lambda$) for EWAS ([@c11]; [@c83]). A Bonferroni threshold was determined at $\alpha = 0.05$, our threshold for epigenome-wide testing. The FDR *p*-values were computed using the Benjamini-Hochberg method ([@c34]). $X^{2}$-tests were applied to compare the distribution of arsenic-associated CpGs to the remaining CpGs across genomic features. UCSC genome (<http://genome.ucsc.edu/>), FANTOM5 ([@c6]), and ENCODE ([@c80]) annotations were provided by Illumina and used to annotate and assign genomic features to CpGs based on human reference genome GRCh37. If CpGs were assigned TSS200 or TSS1500 (at least 200 and 1500 base pairs upstream of transcriptional start site), we annotated these CpGs as being located in a promoter region. DNase I hypersensitive sites (DHS) and TFBS regions were indicated by evidence from ENCODE ([@c80]) while enhancer regions were indicated by supporting evidence from FANTOM5 ([@c6]). In a sensitivity analysis, we also analyzed our data using a reference-based approach, estimating six cell type proportions (monocytes, B-cells, granulocytes, CD8T, CD4T, and natural killer cells) from a whole blood reference panel ([@c35]). For the reference-based approach, we performed linear regression adjusting for estimated cell type proportions and covariates using limma.

Differential Methylation Regional Analysis {#s2.5}
------------------------------------------

We examined associations between urinary arsenic in HEALS and differentially methylated regions (DMRs) using DMRcate ([@c64]). DMRcate is agnostic to the direction of the association for each CpG and all annotations except those related to the spatial location (i.e., chromosome number and map position). DMRs are then defined by agglomerating CpG locations with an adjusted *p*-value below a selected threshold (based on FDR) that are at most $\lambda$ nucleotides from each other. Each DMR is assigned a minimum FDR (minFDR) that is from the lowest adjusted *p*-value among the CpG locations contained within it. We searched for DMRs using a bandwidth of 1,000 nucleotides ($\lambda = 1,000$) and scaling factor of 2 for the bandwidth ($C = 2$) (recommended parameters for $450\; K$ and EPIC arrays). We restricted to DMRs that contained at least two CpGs, and applied a stringent cutoff threshold of $\text{FDR} < \mspace{2mu} 10^{- 4}$. The genomic region for the top three DMRs are visualized using coMET ([@c52]).

Gene Set Enrichment Analyses {#s2.6}
----------------------------

To evaluate the annotation of urinary arsenic--associated CpGs to pathways and biologic processes from the discovery analysis and the meta-analysis, we conducted gene set enrichment analyses (GSEA) using the gometh function in missMethyl ([@c65]). Gometh accounts for the potential bias in GSEA due to number of CpGs per gene by computing prior probabilities ([@c31]) and evaluates enrichment using a hypergeometric test. We tested enrichment among arsenic-associated CpGs among the top 500 arsenic-associated CpGs and arsenic-associated CpGs below FDR of 0.05 within gene sets from the KEGG pathways (<https://www.genome.jp/kegg/>) ($n = 324$ pathways) and hallmark gene set collection ($n = 54$ sets), concise sets curated from multiple founder gene sets and gene expression datasets ([@c49]). Our justification for examining enrichment among the top 500 arsenic-associated CpGs was that it was difficult to examine genomic enrichments among a limited number of arsenic-associated CpGs at an $\text{FDR} < \mspace{2mu} 0.05$, and arsenic likely has numerous biologic effects on the epigenome that might not reach epigenome-wide significance. We extracted results with $p < 0.05$ since our analysis was exploratory and underpowered to detect enrichment at more stringent significance thresholds.

Meta-Analysis {#s2.7}
-------------

We conducted a meta-analysis of genome-wide methylation and urinary arsenic using data from HEALS ($n = 396$) and the BEST cohort ($n = 400$). Using the same procedure applied to the HEALS EPIC array data, we preprocessed, BMIQ normalized, estimated SVs, and analyzed the BEST $450K$ array data. Among the overlapping CpGs in HEALS and BEST ($n = 390,810$), the association estimate and *p*-value for each CpG were obtained from BEST and HEALS and meta-analyzed using the sample size based approach in METAL software ([@c84]).

Gene Expression {#s2.8}
---------------

Gene expression data were only available for the BEST participants included in this study and have been previously described ([@c8]; [@c30]). Briefly, gene expression was measured using the Illumina HT-12 v4 BeadChip according to manufacturer's protocol. The chip includes 37,231 probes and covers 31,335 genes. The gene expression values were quantile normalized and then $\log_{2}\text{ \ transformed}$. COMBAT was used to adjust for batch effect ([@c36]). We extracted gene expression probes corresponding to genes that annotated to our arsenic-associated CpGs identified in the meta-analysis for 371 BEST participants with expression data. To assess the associations between gene expression and methylation, we ran Pearson correlations and linear models adjusted for age and sex, and extracted the direction and *p*-value for each association.

Local Methylation Quantitative Trait Loci (cis-mQTL) Analyses of Arsenic-Associated CpGs {#s2.9}
----------------------------------------------------------------------------------------

HEALS participants were genotyped on the Illumina HumanCytoSNP-12 v2.1 array with 299,140 markers. We used MaCH software ([@c48]) to conduct genotype imputation using 1,000 genomes reference haplotypes (version 5; 1000G Phase 3). We examined cis associations between SNPs and CpGs within a 1-megabase window ($500\text{ \ kb}$ upstream and downstream of the CpG) using genotype dosages and matrixeQTL software ([@c76]). The model was adjusted for age, sex, and first four methylation principal components (PCs). We summarized the total SNPs tested for each CpG and number that reached FDR of 0.01, and reported the genomic information for the lead SNP (smallest *p*-value) and distance from CpG.

Replication Analysis for Meta-Analysis Arsenic-Associated CpGs among Andean Women {#s2.10}
---------------------------------------------------------------------------------

We attempted replication of the urinary arsenic--associated CpGs identified the meta-analysis ($n = 221$) using data from an independent population of Andean women from Argentina that have been previously published ([@c4]). Methylation was measured on the $450\; K$ array for 93 women. For each CpG, the association between methylation (*M*-values) and $\log\text{-transformed}$ urinary arsenic was examined and adjusted for age, coca usage (yes/no), and estimated fractions of granulocyte and natural killer cells. We extracted the direction of association and *p*-value for 217 of our 221 CpGs with available data from the Ameer et al. ([@c4]) analysis.

Results {#s3}
=======

Our HEALS subcohort used for the discovery EWAS ($n = 396$) was randomly drawn from previously genotyped participants in HEALS (also randomly selected). The median age of our subcohort was 36.5 y \[interquartile range (IQR): 30.0, 45.0 y\] ([Table 1](#t1){ref-type="table"}), and there were more women (58%) than men (42%). Current smokers comprised 34% of the HEALS subcohort. At baseline, 76% of our participants consumed water from arsenic-contaminated hand-pumped tube wells with estimated arsenic concentrations above the WHO guideline of $10\;\mu g/L$, and 50% of our participants consumed water with concentrations above the national Bangladesh standard of $50\;\mu g/L$. The median urinary arsenic was $201.5\;\mu g/g$ creatinine (IQR: 113.5, $350.0\;\mu g/g$).

###### 

Subcohort descriptive statistics \[median (25th, 75th percentiles) or *n* (%)\] for HEALS (discovery) and BEST (validation).

Table 1 lists Age (years), urinary arsenic (micrograms per gram), water arsenic (micrograms per liter), sex, smoking, and BMI in the first column and the corresponding values for HEALS Cohort (n equals 11,224), HEALS Subcohort (Discovery, n equals 396), and BEST Subcohort (Validation, n equals 400) in the adjacent columns.

                                HEALS cohort ($n = 11,224$)   HEALS subcohort (discovery; $n = 396$)   BEST subcohort (validation; $n = 400$)
  ----------------------------- ----------------------------- ---------------------------------------- ----------------------------------------
  Age (years)                   36.0 (29.0,45.0)              36.5 (30.0, 45.0)                        44.0 (35.0, 50.3)
  Urinary arsenic ($\mu g/g$)   199.0 (106.0, 352.0)          201.5 (113.5, 350.0)                     137.3 (76.2, 394.4)
  Water arsenic ($\mu g/L$)     60.0 (12.0,147.0)             50.5 (11.0, 124.8)                       Not measured
  Sex                                                                                                  
   Male                         4,855 (43.3%)                 167 (42.2%)                              212 (53.0%)
   Female                       6,369 (56.7%)                 229 (57.8%)                              188 (47.0%)
  Smoking                                                                                              
   Never                        7,204 (64.2%)                 240 (60.6%)                              251 (62.8%)
   Former                       743 (6.6%)                    21 (5.3%)                                40 (10.0%)
   Current                      3,271 (29.1%)                 135 (34.1%)                              109 (27.3%)
   Unknown                      6 (0.1%)                      0 (0.0%)                                 0 (0.0%)
  BMI (${{kg}/m}^{2}$)                                                                                 
   Normal (18.5--22.9)          5,067 (45.1%)                 175 (44.2%)                              176 (44.0%)
   Underweight ($< 18.5$)       4,421 (39.4%)                 154 (38.9%)                              150 (37.5%)
   Overweight (23.0--29.9)      1,575 (14.0%)                 61 (15.4%)                               73 (18.3%)
   Obese ($\geq 30$)            80 (0.7%)                     5 (1.3%)                                 1 (0.3%)
   Unknown                      81 (0.7%)                     1 (0.3%)                                 0 (0.0%)

Note: BEST, Bangladesh Vitamin E and Selenium Trial; BMI, body mass index; HEALS, Health Effects of Arsenic Longitudinal Study.

Urinary arsenic--associated DNA Methylation in HEALS {#s3.1}
----------------------------------------------------

We conducted an EWAS of $\log_{2}\text{-transformed}$ urinary arsenic (creatinine adjusted) using data on 771,192 CpGs measured on the EPIC array among 396 HEALS participants ([Figure 1](#f1){ref-type="fig"}; Figure S1; Excel Table S1). After adjustment for covariates and SVs ($n = 27$), 34 CpGs were associated with $\log_{2}\text{-\ transformed}$ urinary arsenic at an FDR of 0.05 ($p < 2.2 \times 10^{- 6}$) ([Table 2](#t2){ref-type="table"}; Figure S2). From the analysis of beta values (range 0 to 1), the association estimates across these 34 CpGs ranged from 0.016 decrease to a 0.008 increase in methylation per doubling of urinary arsenic. Decreased methylation was associated with increased arsenic exposure for 23 of the 34 associated CpGs ($\text{FDR} < \mspace{2mu} 0.05$). Arsenic-associated CpGs ($\text{FDR} < \mspace{2mu} 0.05$) were predominantly located in CpG shores ($n = 14$) and non-CpG islands ($n = 14$) ([Figure 1B](#f1){ref-type="fig"}). Seven CpGs that passed Bonferroni-threshold ($p < 6.5 \times 10^{- 8}$) were located upstream of the *ABR* (ABR activator of RhoGEF and GTPase) gene on chromosome 17 (cg01912040, cg10003262), in the *SEMA4G* (semaphorin 4G) gene body on chromosome 10 (cg05962511), in the *MAPRE2* (microtubule associated protein RP/EB family member 2) gene body (cg17420142), in the *GBAP1* (glucosylceramidase beta pseudogene 1) gene body (cg06466147), in the *NSMF* gene body (cg09082427), and in the *NBR1* (NBR1 autophagy cargo receptor) 5′ untranslated region (UTR) (cg04193083).

![Genome-wide associations between urinary arsenic concentration and CpG site--specific methylation in the Health Effects of Arsenic Longitudinal Study (HEALS). Using the EPIC ($850K$) array, the association between $\log_{2}\text{-transformed}$ urinary arsenic (creatinine adjusted) and methylation was evaluated at 771,192 CpG sites across 396 individuals from HEALS. (A) Manhattan plot of the chromosomal location and *p*-value for each CpG--arsenic association. (B) Volcano plot presenting association estimate and *p*-value for each CpG--arsenic association. Colors correspond to CpG relationship to island. In (A) and (B), solid and dashed lines designate the Bonferroni threshold ($p = 6.5 \times 10^{- 8}$) and false discovery rate (FDR) 0.05 threshold ($p = 2.0 \times 10^{- 6}$), respectively.](ehp-127-057011-g0001){#f1}

###### 

CpGs associated with $\log_{2}\text{-transformed}$ urinary arsenic ($\text{false\ discovery\ rate\  }\left( \text{FDR} \right) < 0.05$) discovered in HEALS (EPIC array).

Table 2 lists Name, Chromosome number, position, CpG location, Nearest gene, feature, distance in the first eight columns, followed by mean (SD), beta sub sva values, p sub sva values, and p sub cell-adjusted values for HEALS (Discovery) and mean (SD), beta sub sva values, and p sub sva values for BEST (Validation).

               HEALS (discovery, EPIC)   BEST[^*d*^](#TF6){ref-type="table-fn"} (validation 450 K)                                                                                                                                                             
  ------------ ------------------------- ----------------------------------------------------------- ---------------- ------------ ------------ --------- ------------- ----------- ------------------------ ----------------------- ------------- ----------- -----------------------
  cg01912040   17                        1106553                                                     Shore            *ABR*        Upstream     15,937    0.73 (0.05)   $- 0.013$   $4.2 \times 10^{- 13}$   $4.0 \times 10^{- 9}$   0.72 (0.06)   $- 0.008$   $2.8 \times 10^{- 6}$
  cg05962511   10                        102730022                                                   Shore            *SEMA4G*     Body         732       0.35 (0.05)   $- 0.011$   $2.8 \times 10^{- 12}$   $3.9 \times 10^{- 8}$   0.34 (0.05)   $- 0.004$   $6.6 \times 10^{- 4}$
  cg10003262   17                        1106589                                                     Shore            *ABR*        Upstream     15,973    0.34 (0.06)   $- 0.014$   $2.4 \times 10^{- 11}$   $6.3 \times 10^{- 9}$   0.26 (0.05)   $- 0.007$   $4.9 \times 10^{- 6}$
  cg17420142   18                        32702783                                                    Non-CpG island   *MAPRE2*     Body         81,169    0.59 (0.05)   $- 0.011$   $3.1 \times 10^{- 10}$   $1.7 \times 10^{- 6}$   ---           ---         ---
  cg06466147   1                         155188982                                                   Non-CpG island   *GBAP1*      Body         19,459    0.62 (0.07)   $- 0.016$   $6.2 \times 10^{- 9}$    $2.0 \times 10^{- 9}$   ---           ---         ---
  cg09082427   9                         140349184                                                   Shore            *NSMF*       Body         4,602     0.75 (0.05)   $- 0.007$   $9.9 \times 10^{- 9}$    $4.3 \times 10^{- 6}$   ---           ---         ---
  cg04193083   17                        41323562                                                    Shore            *NBR1*       5\'UTR       316       0.04 (0.02)   0.002       $3.3 \times 10^{- 8}$    $7.0 \times 10^{- 1}$   0.03 (0.01)   0.000       $4.1 \times 10^{- 1}$
  cg19534475   3                         141632139                                                   Non-CpG island   *ATP1B3*     Body         36,669    0.47 (0.04)   0.008       $9.6 \times 10^{- 8}$    $4.6 \times 10^{- 8}$   ---           ---         ---
  cg12608784   9                         140349197                                                   Shore            *NSMF*       Body         4,589     0.69 (0.05)   $- 0.007$   $1.2 \times 10^{- 7}$    $2.3 \times 10^{- 5}$   ---           ---         ---
  cg14891900   17                        76341204                                                    Shelf            *SOCS3*      Downstream   14,954    0.91 (0.01)   0.003       $1.3 \times 10^{- 7}$    $1.8 \times 10^{- 7}$   0.93 (0.01)   $- 0.001$   $3.2 \times 10^{- 3}$
  cg11308227   17                        79202435                                                    Non-CpG island   *ENTHD2*     3\'UTR       10,456    0.54 (0.06)   $- 0.011$   $1.3 \times 10^{- 7}$    $1.6 \times 10^{- 6}$   ---           ---         ---
  cg13832772   4                         186283800                                                   Non-CpG island   *SNX25*      Body         41,913    0.87 (0.03)   $- 0.005$   $1.7 \times 10^{- 7}$    $1.4 \times 10^{- 2}$   0.94 (0.02)   0.000       $6.2 \times 10^{- 1}$
  cg15108641   10                        99263320                                                    Shelf            *UBTD1*      Body         4,552     0.35 (0.06)   0.008       $2.5 \times 10^{- 7}$    $2.8 \times 10^{- 5}$   ---           ---         ---
  cg09658504   9                         140349188                                                   Shore            *NSMF*       Body         4,598     0.47 (0.04)   $- 0.005$   $3.0 \times 10^{- 7}$    $7.4 \times 10^{- 4}$   ---           ---         ---
  cg05438461   15                        40401720                                                    Shore            *BMF*        Promoter     632       0.20 (0.03)   0.005       $3.5 \times 10^{- 7}$    $2.4 \times 10^{- 5}$   ---           ---         ---
  cg10663081   20                        36837543                                                    Non-CpG island   *KIAA1755*   Downstream   51,631    0.47 (0.03)   $- 0.004$   $3.7 \times 10^{- 7}$    $1.5 \times 10^{- 5}$   ---           ---         ---
  cg08759026   11                        69061454                                                    Non-CpG island   *MYEOV*      Promoter     159       0.24 (0.04)   $- 0.004$   $6.7 \times 10^{- 7}$    $4.8 \times 10^{- 6}$   0.27 (0.04)   $- 0.003$   $7.7 \times 10^{- 5}$
  cg11644394   7                         144148615                                                   Non-CpG island   *TPK1*       Downstream   419       0.62 (0.06)   0.008       $7.5 \times 10^{- 7}$    $5.3 \times 10^{- 4}$   ---           ---         ---
  cg05428706   10                        102730130                                                   Shore            *SEMA4G*     Body         840       0.79 (0.04)   $- 0.008$   $8.2 \times 10^{- 7}$    $1.8 \times 10^{- 5}$   0.76 (0.04)   $- 0.005$   $1.3 \times 10^{- 4}$
  cg12865207   3                         138669373                                                   Shore            *FOXL2NB*    Body         3,297     0.15 (0.03)   0.004       $1.0 \times 10^{- 6}$    $3.4 \times 10^{- 3}$   ---           ---         ---
  cg09183146   16                        1429863                                                     Island           *UNKL*       Promoter     34,842    0.26 (0.05)   $- 0.01$    $1.2 \times 10^{- 6}$    $3.4 \times 10^{- 6}$   0.24 (0.05)   $- 0.007$   $2.4 \times 10^{- 5}$
  cg04622454   9                         140349128                                                   Shore            *NELF*       Body         4,658     0.63 (0.04)   $- 0.005$   $1.3 \times 10^{- 6}$    $6.1 \times 10^{- 3}$   0.57 (0.04)   $- 0.003$   $1.1 \times 10^{- 3}$
  cg06381803   19                        46119475                                                    Island           *EML2*       Body         29,300    0.41 (0.07)   $- 0.012$   $1.4 \times 10^{- 6}$    $8.8 \times 10^{- 6}$   0.40 (0.07)   $- 0.009$   $7.9 \times 10^{- 6}$
  cg02772605   1                         28912323                                                    Shelf            *SNHG12*     Upstream     3957      0.88 (0.02)   0.003       $1.4 \times 10^{- 6}$    $2.7 \times 10^{- 6}$   0.89 (0.02)   0.000       $9.4 \times 10^{- 1}$
  cg10283165   19                        17375666                                                    Non-CpG island   *USHBP1*     Promoter     61        0.39 (0.05)   $- 0.006$   $1.4 \times 10^{- 6}$    $1.3 \times 10^{- 3}$   ---           ---         ---
  cg04891961   17                        27939900                                                    Island           *ANKRD13B*   Body         19,373    0.49 (0.07)   $- 0.009$   $1.4 \times 10^{- 6}$    $1.6 \times 10^{- 5}$   0.47 (0.08)   0.002       $1.8 \times 10^{- 1}$
  cg12746706   6                         169276508                                                   Non-CpG island   *SMOC2*      Upstream     207,834   0.86 (0.03)   $- 0.005$   $1.5 \times 10^{- 6}$    $8.2 \times 10^{- 3}$   0.94 (0.01)   $- 0.001$   $1.3 \times 10^{- 1}$
  cg02330195   10                        73342047                                                    Non-CpG island   *CDH23*      Body         142,463   0.67 (0.04)   0.005       $1.5 \times 10^{- 6}$    $3.7 \times 10^{- 3}$   ---           ---         ---
  cg08077890   18                        157838                                                      Shore            *USP14*      Promoter     645       0.77 (0.04)   0.006       $1.6 \times 10^{- 6}$    $1.4 \times 10^{- 3}$   ---           ---         ---
  cg20433952   17                        55607898                                                    Non-CpG island   *MSI2*       Body         273,524   0.51 (0.04)   $- 0.008$   $1.9 \times 10^{- 6}$    $4.4 \times 10^{- 3}$   0.52 (0.04)   $- 0.003$   $3.4 \times 10^{- 2}$
  cg10185759   12                        60366859                                                    Non-CpG island   *SLC16A7*    Downstream   283,741   0.46 (0.04)   $- 0.007$   $1.9 \times 10^{- 6}$    $1.3 \times 10^{- 7}$   ---           ---         ---
  cg05646745   10                        135172466                                                   Shore            *FUOM*       Promoter     937       0.73 (0.04)   0.005       $1.9 \times 10^{- 6}$    $4.0 \times 10^{- 7}$   ---           ---         ---
  cg22345623   9                         125050297                                                   Non-CpG island   *MRRF*       Body         17,154    0.78 (0.05)   $- 0.007$   $2.0 \times 10^{- 6}$    $2.3 \times 10^{- 7}$   ---           ---         ---
  cg13480898   19                        10195914                                                    Shore            *C19orf66*   Promoter     892       0.73 (0.05)   $- 0.005$   $2.0 \times 10^{- 6}$    $2.8 \times 10^{- 7}$   0.76 (0.04)   $- 0.007$   $3.7 \times 10^{- 8}$

Note: Results from the discovery analysis are shown for CpGs associated with $\log_{2}\text{-transformed}$ urinary arsenic (creatinine adjusted) below false discovery rate (FDR) of 0.05 from models adjusted for age, sex, BMI category, smoking status, and 27 SVs. The *p*-values are obtained from the analyses using methylation expressed as *M*-values as the outcome variable, and reported association estimates ($\beta_{\text{sva}}$) are from analysis with methylation expressed as beta values as the outcome variable (for easier interpretability). Gene assignments are from UCSC gene annotation provided by Illumina. The replication results from BEST are also presented for the CpGs measured on both the EPIC and $450K$ arrays. Extended results for arsenic-associated CpGs with $p < 0.05$ are presented in Excel Table S1. ---, no data; BEST, Bangladesh Vitamin E and Selenium Trial; BMI, body mass index; Chr, chromosome; HEALS, Health Effects of Arsenic Longitudinal Study; SD, standard deviation; SV, surrogate variable.

Mean and SD of beta values at each CpG (range: 0 to 1) in HEALS and BEST.

$\beta_{\text{sva}}$ and $p_{\text{sva}}$ are association estimate and *p*-value from covariate and SV-adjusted analysis model.

$p_{\text{cell\ adjusted}}$ is *p*-value from the analysis model of $\log_{2}\text{-transformed}$ urinary arsenic and adjusted for covariates and estimated cell type proportions.

Results from the replication analysis in BEST are shown for $\log_{2}\text{-transformed}$ urinary arsenic--CpG associations from models adjusted for age, sex, BMI category, smoking status, and 24 SVs.

The results from the $\log_{2}\text{-transformed}$ urinary arsenic analysis were compared with results from analyses where urinary arsenic was modeled as an untransformed continuous or an ordinal quartile (integer-coded) variable. Across arsenic exposure models, the genomic inflation was similar, and all untransformed continuous and ordinal quartile arsenic-associated CpGs ($p < 0.05$) overlapped with $\log_{2}\text{-transformed}$ arsenic-associated CpGs ($\text{FDR} < \mspace{2mu} 0.05$; $n = 34$) (Table S1). Among the 34 arsenic-associated CpGs identified ($\text{FDR} < \mspace{2mu} 0.05$), 31 were significantly associated with $\log_{2}\text{-\ transformed}$ urinary arsenic ($p < 0.05$) prior to adjustment for covariates and SVs. Of the 34 arsenic-associated CpGs identified from the SV model, 68% ($n = 23$) and 97% ($n = 33$) were also associated with urinary arsenic at FDR of 0.05 and $p < 0.05$, respectively, in the cell type--adjusted model. When we examined the associations between urinary arsenic and estimated cell type proportions, $\log_{2}\text{-transformed}$ urinary arsenic was associated with decreased CD4T percentage \[$\beta = - 0.5$ (0.2); $p = 0.01$\] and increased granulocyte percentage \[$\beta = 0.8$ (0.4); $p = 0.05$\] after adjustment for age, sex, smoking status, and BMI (Table S2), suggesting that urinary arsenic was modestly associated with variation in estimated cell composition.

Among the 34 urinary arsenic--associated CpGs ($\text{FDR} < \mspace{2mu} 0.05$) discovered in HEALS, we attempted replication for the 16 CpGs present on the $450\; K$ array using previously measured $450\; K$ methylation data from 400 BEST participants. Ten CpGs replicated with consistent direction of association in BEST ($p < 0.05$) ([Table 2](#t2){ref-type="table"}). Among the urinary arsenic--associated CpGs discovered in HEALS at the $p = 10^{- 5}$ threshold ($n = 67$), 26 CpGs were measured in BEST ([Figure 2](#f2){ref-type="fig"}; Excel Table S1). Among these 26 CpGs, 15 (58%) were associated with urinary arsenic ($p < 0.05$), and 14 (93%) were directionally consistent in BEST.

![Associations between urinary arsenic and CpG methylation discovered in the Health Effects of Arsenic Longitudinal Study (HEALS) and tested for replication in the Bangladesh Vitamin E and Selenium Trial (BEST). Using results from BEST, we attempted to validate 26 arsenic-associated CpGs that annotated to $450K$ array among the 67 CpGs identified using the EPIC array in HEALS ($p < 10^{- 5}$). The BEST results consisted of associations between $\log_{2}\text{-transformed}$ urinary arsenic and methylation evaluated for 390,810 CpGs using data on 400 BEST participants with existing $450K$ array data. Horizontal dashed line represents $- \,\log_{10}\left( {p = 0.05} \right)$, and solid vertical line corresponds to $- \,\log_{10}\left\lbrack {\text{false\ discovery\ rate\  }\left( \text{FDR} \right) < 0.05} \right\rbrack$. Direction of association summarizes whether results from the cohorts are both positive (triangle), both negative (square), or inconsistent (directions of association differ) (circle). The corresponding results data are presented in [Table 2](#t2){ref-type="table"} and Excel Table S1.](ehp-127-057011-g0002){#f2}

Water Arsenic--Associated DNA Methylation in HEALS {#s3.2}
--------------------------------------------------

To examine whether urinary arsenic--associated CpGs were consistent across different exposure assessments of arsenic, we examined arsenic in drinking water and its association with genome-wide methylation. Both water and urinary arsenic were measured in HEALS, and the correlation between the two measures was 0.61 ($p < 10^{- 16}$) (Figure S3). Four CpGs passed a Bonferroni threshold ($p < 6.5 \times 10^{- 8}$) when we assessed associations with $\log_{2}\text{-transformed}$ water arsenic (Figures S4; Figure S5; Excel Table S2). At an FDR of 0.05, 24 water arsenic--associated CpGs were identified. Among the urinary arsenic--associated CpGs ($n = 34$, $\text{FDR} < 0.05$), all 34 CpGs were associated with water arsenic (i.e., $p < 0.05$ and consistent direction), and eight were associated at a FDR of 0.05. When we examined all CpG methylation and arsenic associations across the epigenome for both water and urine, the correlation between the $- \,\log_{10}\left( {p\text{-values}} \right)$ and direction of association was 0.67 ($p < 10^{- 16}$), mirroring the correlation we observed between the two exposures ([Figure 3](#f3){ref-type="fig"}).

![Comparison between the associations of urinary arsenic and water arsenic with genome-wide methylation in the Health Effects of Arsenic Longitudinal Study (HEALS). The direction of association and $- \,\log_{10}\left( p \right)$ for each CpG--arsenic association are plotted for urinary (*x*-axis) and water (*y*-axis) (both $\log_{2}\text{ \ transformed}$). Solid lines and dashed lines designate $- \,\log_{10}\left( {p = 1} \right)$ and $- \,\log_{10}\left( {p = 0.05} \right)$, respectively. CpGs highlighted in blue diamonds denote $\log_{2}\text{-transformed}$ urinary arsenic--associated sites \[$\text{false\ discovery\ rate\  }\left( \text{FDR} \right) < 0.05$\]. Pearson's correlation between all urinary and water arsenic CpG associations was 0.67 ($p < 10^{- 16}$).](ehp-127-057011-g0003){#f3}

Arsenic-Associated Regions in HEALS {#s3.3}
-----------------------------------

To identify regions of DNA methylation associated with urinary arsenic, we searched for DMRs using the DMRcate method. We identified 45 DMRs with $\text{minFDR} < 10^{- 4}$ ([Figure 4A](#f4){ref-type="fig"}; Table S3). Eight CpGs individually associated with urinary arsenic ($p < 6.5 \times 10^{- 8}$) annotated to six of these DMRs based on region start and end locations (see CpG location in [Table 2](#t2){ref-type="table"}). The average methylation decreased with increased urinary arsenic in 64.4% ($n = 29$) of these DMRs. Most DMRs (82.2%; $n = 37$) contained CpGs annotated to a gene; however, we also identified eight intergenic DMRs. Among the DMRs that annotated to a gene, the DMRs most frequently spanned promoters ($n = 19$), gene bodies ($n = 17$), and 5′UTRs ($n = 11$). The top three DMRs were *a*) upstream of *ABR* on chromosome 17 ($\text{minFDR} = 6.4 \times 10^{- 26}$), overlapping an enhancer region ([Figure 4B](#f4){ref-type="fig"}); *b*) in the body of *SEMA4G* on chromosome 10 ($\text{minFDR} = 6.7 \times 10^{- 20}$), overlapping a weak promoter ([Figure 4C](#f4){ref-type="fig"}); and *c*) a region within the *NSMF* gene on chromosome 9 ($\text{minFDR} = 6.7 \times 10^{- 20}$), overlapping an enhancer region ([Figure 4D](#f4){ref-type="fig"}). All three regions spanned a DNase cluster region. The mean effect size related to the $\log_{2}\text{-transformed}$ arsenic-associated change in DNA methylation (beta values) across the DMR was $- 0.008$ for *ABR*, $- 0.003$ for *SEMA4G*, and $- 0.005$ for *NSMF*.

![Differentially methylated regions (DMRs) associated with $\log_{2}\text{-transformed}$ urinary arsenic in the Health Effects of Arsenic Longitudinal Study (HEALS). Using 771,192 CpGs from the EPIC array, DMRs were identified using DMRcate ($\lambda = 1,000$ base pairs and $C = 2$). (A) Manhattan plot of the minimum false discovery rate (minFDR) for the CpG within all regions identified across EPIC array (no significance threshold set) ($n = 108,086$ regions). Solid and dashed lines designate minFDR of $10^{- 4}$ and minFDR of 0.05, respectively. (B--D) coMET plots of top three DMRs associated with urinary arsenic. Genomic annotations to gene, CpG islands, chromatin regulation, and DNase clusters are shown below each plot and are from UCSC CpG Island, UCSC DNase Cluster, and the Broad UCSC ChromatinHMM tracks (<http://genome.ucsc.edu/>, see coMET software documentation for further information and color coding) ([@c52]).](ehp-127-057011-g0004){#f4}

Enrichment of Arsenic-Associated CpGs within Genomic Features and Gene Sets {#s3.4}
---------------------------------------------------------------------------

We examined the enrichment of arsenic-associated CpGs within promoters, enhancers, TFBS, and DHS regions. Arsenic-associated CpGs ($\text{FDR} < 0.05$) were enriched in shores and depleted in islands compared with CpGs not associated with arsenic ($p = 3.9 \times 10^{- 3}$) \[see "Discovery (EPIC)" in [Figure 5A](#f5){ref-type="fig"}\]. We observed no enrichment/depletion of arsenic-associated CpGs in gene regions, promoters, TFBS, and enhancers. Arsenic-associated CpGs were 29% more likely to be annotated to DHS regions ($p = 0.04$) \[see "Discovery (EPIC)" in [Figure 5B](#f5){ref-type="fig"}\].

![Enrichment of arsenic-associated CpGs among genomic features at $\text{false\ discovery\ rate\  }\left( \text{FDR} \right)\text{ \ of\  }0.05$. (A) Locational (with relation to island) distribution of $\log_{2}\text{-transformed}$ arsenic-associated CpGs ($\text{FDR} < 0.05$) from the Health Effects of Arsenic Longitudinal Study (HEALS) discovery analysis on EPIC array ($n = 34$ CpGs) and meta-analysis of HEALS and the Bangladesh Vitamin E and Selenium Trial (BEST) ($n = 221$ CpGs) compared with distribution of CpGs on entire EPIC ($n = 771,158$) and $450K$ ($n = 390,589$) array, respectively. Colors correspond to CpG relationship to island. (B) Fold enrichment (FE) is plotted for each genomic feature comparing urinary arsenic--associated CpGs below FDR of 0.05 to the remaining CpGs. CpGs annotating to a promoter region were defined as those annotating to TSS200 or TSS1500. Abbreviations correspond to transcription factor binding site (TFBS) and DNase I hypersensitive site (DHS). *P*-values were obtained from $X^{2}\text{-test}$ comparing distribution of CpGs above and below FDR of 0.05 for each genomic feature \[$p < 0.05$ (\*), $p < 10^{- 3}$ (\*\*), and $p < 10^{- 6}$ (\*\*\*)\].](ehp-127-057011-g0005){#f5}

GSEA was applied to the urinary arsenic--associated CpGs discovered in HEALS. No gene sets were enriched among the genes annotated to the arsenic-associated CpGs at FDR of 0.05 (21 unique genes). We assessed enrichment of hallmark gene sets among the genes that annotated to our top 500 arsenic-associated CpGs (348 unique genes) (see "HEALS" in [Table 3](#t3){ref-type="table"}) and observed enrichment for genes annotated to the tumor necrosis factor $\alpha$ ($\text{TNF}\alpha$) signaling via $\text{NF}\kappa B$ hallmark (seven genes; $p = 0.02$), cholesterol homeostasis (four genes; $p = 0.01$), and angiogenesis (three genes; $p = 6.4 \times 10^{- 3}$). Among KEGG pathways, the hematopoietic cell lineage pathway was significantly enriched (four genes; $p = 0.04$) (Table S4).

###### 

Results from gene set enrichment analysis of hallmark gene set collection ($n = 54$ sets) among the urinary arsenic--associated CpGs identified in the HEALS discovery analysis ($n = 396$) and meta-analysis of HEALS and BEST ($n = 796$).

Table 3 lists HEALS discovery analysis and Meta-analysis of HEALS and BEST in the first column and n values in the second column. The adjacent columns list genes and p values for top 500 arsenic-associated CpGs and Arsenic-associated CpGs below FDR less than 0.05.

                                                          Top 500 arsenic-associated CpGs[^*a*^](#TF8){ref-type="table-fn"}   Arsenic-associated CpGs below $\text{FDR} < \mspace{2mu} 0.05$[^*b*^](#TF9){ref-type="table-fn"}                                 
  ------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------- ----- -----------------------
  HEALS                                                                                                                                                                                                                                                        
   Angiogenesis                                           36                                                                  3                                                                                                  $6.4 \times 10^{- 3}$   ---   ---
   Cholesterol homeostasis                                74                                                                  4                                                                                                  $1.2 \times 10^{- 2}$   ---   ---
   $\text{TNF}\alpha$ signaling via $\text{NF}\kappa B$   200                                                                 7                                                                                                  $2.1 \times 10^{- 2}$   ---   ---
  META-ANALYSIS                                                                                                                                                                                                                                                
   Allograft rejection                                    200                                                                 9                                                                                                  $2.2 \times 10^{- 3}$   4     $1.9 \times 10^{- 2}$
   $\text{PI}_{3}K/\text{AKT}/\text{mTOR}$                105                                                                 6                                                                                                  $9.8 \times 10^{- 3}$   3     $2.2 \times 10^{- 2}$
   Reactive oxygen species pathway                        49                                                                  3                                                                                                  $1.4 \times 10^{- 2}$   2     $9.1 \times 10^{- 3}$
   Inflammatory response                                  200                                                                 6                                                                                                  $2.9 \times 10^{- 2}$   3     $4.4 \times 10^{- 2}$
   $\text{TNF}\alpha$ signaling via $\text{NF}\kappa B$   200                                                                 7                                                                                                  $4.1 \times 10^{- 2}$   4     $3.1 \times 10^{- 2}$
   Estrogen response early                                200                                                                 10                                                                                                 $1.1 \times 10^{- 2}$   ---   ---
   UV response up-regulated                               158                                                                 7                                                                                                  $1.4 \times 10^{- 2}$   ---   ---
   *MTORC1* signaling                                     200                                                                 ---                                                                                                ---                     4     $1.8 \times 10^{- 2}$
   Oxidative phosphorylation                              200                                                                 ---                                                                                                ---                     3     $3.1 \times 10^{- 2}$
   *MYC* targets V1                                       200                                                                 ---                                                                                                ---                     3     $4.7 \times 10^{- 2}$
   Apical junction                                        200                                                                 ---                                                                                                ---                     4     $4.8 \times 10^{- 2}$

Note: Gene annotations for arsenic-associated CpGs are provided as gene set input for the gometh function. Results are presented for hallmark gene sets ($n = 54$ sets) with at least two genes from arsenic-associated CpG gene set and enrichment ($p < 0.05$). Background gene set for $450\; K$ is 19,246 genes, and EPIC is 23,234 genes. The table reports total number of genes in set (*n*), genes identified in pathway from CpG gene set, and *p*-value from CpG bias-corrected hypergeometric test. ---, no data; BEST, Bangladesh Vitamin E and Selenium Trial; FDR, false discovery rate; HEALS, Health Effects of Arsenic Longitudinal Study; $\text{TNF}\alpha$, tumor necrosis factor $\alpha$.

Top 500 arsenic-associated CpGs, annotated to 348 unique genes in the HEALS discovery analysis (EPIC array), 338 unique genes in the meta-analysis ($450\; K$ array).

Arsenic-associated CpGs ($\text{FDR} < \mspace{2mu} 0.05$), annotated to 21 unique genes in the discovery analysis, 153 unique genes in the meta-analysis.

Meta-Analysis of Urinary Arsenic and Genome-Wide DNA Methylation in HEALS and BEST {#s3.5}
----------------------------------------------------------------------------------

We conducted a meta-analysis of 390,810 CpGs measured in both HEALS and BEST (see Figure S6 and Figure S7 for full results) to more robustly identify urinary arsenic--associated CpGs. This meta-analysis identified 41 CpGs passing the Bonferroni threshold ($p < 1.3 \times 10^{- 7}$) ([Figure 6](#f6){ref-type="fig"}; [Table 4](#t4){ref-type="table"}). At an FDR of 0.05, 221 urinary arsenic--associated CpGs were identified, and all had consistent direction of association in each study ($p < 2.8 \times 10^{- 5}$) (Excel Table S3). Among the 41 arsenic-associated CpGs ($p < 1.3 \times 10^{- 7}$), 34 (82.9%) were negatively associated with increased exposure, and this pattern of hypomethylation with increased arsenic persisted among associated CpGs with FDR of 0.05 ($n = 170$, 76.9%) ([Table 4](#t4){ref-type="table"}). Our top two arsenic-associated CpGs were located upstream of *ABR* (cg01912040, cg10003262*)*. The remaining CpGs of the top 10 CpGs annotated to the upstream region of *SEMA4G* (cg05962511), *C19orf66* promoter (cg13480898), *EFNA1* (ephrin A1) gene body (cg07207669), *SQSTM1* (sequestosome 1) 5'UTR (cg01225779), *EML2* (echinoderm 486 microtubule associated protein like 2) gene body (cg06381803), *UNKL* (unk like zinc finger) TSS200 (cg09183146), *MYEOV* (myeloma overexpressed) promoter (cg08759026), and *SPSB1* (splA/ryanodine receptor domain and SOCS box containing 1) 5'UTR (cg17489312).

![Epigenome-wide meta-analysis of associations between urinary arsenic and DNA methylation in Bangladeshi adults using data from the Health Effects of Arsenic Longitudinal Study (HEALS) and the Bangladesh Vitamin E and Selenium Trial (BEST). Using data from EPIC (HEALS; $n = 396$) and $450K$ (BEST; $n = 400$) arrays, 390,810 CpG sites were meta-analyzed using METAL \[summary statistics from covariate- and surrogate variable (SV)--adjusted model were provided as input\]. (A) Q-Q plot of the observed distribution of meta-analysis *p*-values. The red line represents expected distribution of *p*-values under the null, and $\lambda$ corresponds to the genomic inflation factor (see "Methods" section). (B) Manhattan plot of the location of each CpG and *p*-value for each CpG--arsenic association. Solid and dashed lines designate the Bonferroni threshold ($p = 1.3 \times 10^{- 7}$) and false discovery rate (FDR) 0.05 threshold ($p = 2.8 \times 10^{- 5}$), respectively.](ehp-127-057011-g0006){#f6}

###### 

CpGs Associated with $\log_{2}\text{-transformed}$ urinary arsenic ($p < 1.3 \times 10^{- 7}$) from meta-analysis of HEALS ($n = 396$) and BEST ($n = 400$).

Table 4 lists Name, Chromosome number, Position, CpG Location, Nearest Gene, Feature, Distance, Direction of Association, and p values from Meta-analysis.

  Name         Chr   Position    CpG location      Nearest gene   Feature      Distance (basepairs)   Direction of association                *p*
  ------------ ----- ----------- ----------------- -------------- ------------ ---------------------- --------------------------------------- ------------------------
  cg01912040   17    1106553     Shore             *ABR*          Upstream     15,937                 $\left. \downarrow\downarrow \right.$   $3.3 \times 10^{- 17}$
  cg10003262   17    1106589     Shore             *ABR*          Upstream     15,973                 $\left. \downarrow\downarrow \right.$   $1.9 \times 10^{- 15}$
  cg05962511   10    102730022   Shore             *SEMA4G*       Body         732                    $\left. \downarrow\downarrow \right.$   $2.1 \times 10^{- 13}$
  cg13480898   19    10195914    Shore             *C19orf66*     Promoter     892                    $\left. \downarrow\downarrow \right.$   $4.1 \times 10^{- 13}$
  cg07207669   1     155102388   Shore             *EFNA1*        Body         2,039                  $\left. \downarrow\downarrow \right.$   $3.0 \times 10^{- 12}$
  cg01225779   5     179238472   Shelf             *SQSTM1*       5\'UTR       4,148                  $\left. \downarrow\downarrow \right.$   $1.0 \times 10^{- 11}$
  cg06381803   19    46119475    Island            *EML2*         Body         29,300                 $\left. \downarrow\downarrow \right.$   $4.8 \times 10^{- 11}$
  cg09183146   16    1429863     Island            *UNKL*         Promoter     34,842                 $\left. \downarrow\downarrow \right.$   $1.4 \times 10^{- 10}$
  cg08759026   11    69061454    Non-CpG island    *MYEOV*        Promoter     159                    $\left. \downarrow\downarrow \right.$   $2.8 \times 10^{- 10}$
  cg17489312   1     9376039     Non-CpG island2   *SPSB1*        5\'UTR       23,098                 $\left. \downarrow\downarrow \right.$   $2.9 \times 10^{- 10}$
  cg00472758   16    2552820     Shelf             *TBC1D24*      3\'UTR       4,581                  $\left. \downarrow\downarrow \right.$   $5.6 \times 10^{- 10}$
  cg05428706   10    102730130   Shore             *SEMA4G*       Inside       840                    $\left. \downarrow\downarrow \right.$   $5.8 \times 10^{- 10}$
  cg05425326   16    58439361    Non-CpG island    *GINS3*        3\'UTR       13,063                 $\left. \uparrow\uparrow \right.$       $6.1 \times 10^{- 10}$
  cg26435149   3     55605611    Non-CpG island    *ERC2*         3\'UTR       896,780                $\left. \downarrow\downarrow \right.$   $7.3 \times 10^{- 10}$
  cg17393635   19    49843565    Island            *CD37*         Body         4,888                  $\left. \downarrow\downarrow \right.$   $1.2 \times 10^{- 9}$
  cg13223043   1     26492308    Shore             *FAM110D*      Upstream     3,189                  $\left. \downarrow\downarrow \right.$   $2.5 \times 10^{- 9}$
  cg03871754   17    79320652    Island            *TMEM105*      Upstream     16,178                 $\left. \downarrow\downarrow \right.$   $3.3 \times 10^{- 9}$
  cg19240637   2     7172297     Island            *RNF144A*      Body         114,774                $\left. \downarrow\downarrow \right.$   $3.7 \times 10^{- 9}$
  cg07782285   19    13085442    Non-CpG island    *DAND5*        3\'UTR       5,118                  $\left. \downarrow\downarrow \right.$   $7.5 \times 10^{- 9}$
  cg26390598   21    41032396    Non-CpG island    *B3GALT5*      5\'UTR       3,142                  $\left. \uparrow\uparrow \right.$       $1.0 \times 10^{- 8}$
  cg04622454   9     140349128   Shore             *NELF*         Body         4,658                  $\left. \downarrow\downarrow \right.$   $1.1 \times 10^{- 8}$
  cg22959742   10    13913931    Non-CpG island    *FRMD4A*       Body         136,229                $\left. \uparrow\uparrow \right.$       $1.3 \times 10^{- 8}$
  cg00281776   2     209224225   Shore             *PTH2R*        Promoter     344                    $\left. \downarrow\downarrow \right.$   $1.8 \times 10^{- 8}$
  cg12261095   19    7764345     Non-CpG island    *FCER2*        Body         2,687                  $\left. \downarrow\downarrow \right.$   $2.0 \times 10^{- 8}$
  cg14718533   10    33355576    Non-CpG island    *ITGB1*        Upstream     108,283                $\left. \uparrow\uparrow \right.$       $2.1 \times 10^{- 8}$
  cg04459545   19    17375685    Non-CpG island    *USHBP1*       Promoter     61                     $\left. \downarrow\downarrow \right.$   $3.1 \times 10^{- 8}$
  cg14145338   9     139649039   Non-CpG island    *LCN8*         Body         3,692                  $\left. \downarrow\downarrow \right.$   $3.3 \times 10^{- 8}$
  cg04920032   12    50262986    Non-CpG island    *FAIM2*        3\'UTR       34,774                 $\left. \downarrow\downarrow \right.$   $3.5 \times 10^{- 8}$
  cg18413900   12    58160989    Shore             *CYP27B1*      Promoter     13                     $\left. \uparrow\uparrow \right.$       $3.6 \times 10^{- 8}$
  cg01757312   13    112720565   Island            *SOX1*         Promoter     1,348                  $\left. \uparrow\uparrow \right.$       $3.7 \times 10^{- 8}$
  cg05816193   6     26018127    Shelf             *HIST1H1A*     Promoter     87                     $\left. \downarrow\downarrow \right.$   $4.4 \times 10^{- 8}$
  cg07367302   1     19967428    Shelf             *MINOS-NBL1*   Body         43,957                 $\left. \downarrow\downarrow \right.$   $4.6 \times 10^{- 8}$
  cg02306995   3     122635049   Shelf             *SEMA5B*       Body         111,610                $\left. \downarrow\downarrow \right.$   $5.5 \times 10^{- 8}$
  cg24318728   17    39649283    Non-CpG island    *KRT36*        Downstream   484                    $\left. \downarrow\downarrow \right.$   $5.9 \times 10^{- 8}$
  cg04875062   1     17305562    Shore             *MFAP2*        5\'UTR       2,519                  $\left. \downarrow\downarrow \right.$   $6.0 \times 10^{- 8}$
  cg13764516   9     139648911   Non-CpG island    *LCN8*         3\'UTR       3,820                  $\left. \downarrow\downarrow \right.$   $6.5 \times 10^{- 8}$
  cg23050300   1     3281321     Non-CpG island    *PRDM16*       Body         295,579                $\left. \downarrow\downarrow \right.$   $8.4 \times 10^{- 8}$
  cg18050715   13    97996992    Shore             *MBNL2*        Body         69,106                 $\left. \uparrow\uparrow \right.$       $8.7 \times 10^{- 8}$
  cg04826368   6     27130208    Non-CpG island    *HIST1H2AH*    Upstream     14,867                 $\left. \downarrow\downarrow \right.$   $1.0 \times 10^{- 7}$
  cg08596618   1     24275885    Non-CpG island    *SRSF10*       Downstream   31,068                 $\left. \downarrow\downarrow \right.$   $1.1 \times 10^{- 7}$
  cg27092191   16    31884699    Shore             *ZNF267*       Promoter     380                    $\left. \downarrow\downarrow \right.$   $1.2 \times 10^{- 7}$

Note: Results from meta-analysis are shown CpGs associated with $\log_{2}\text{-transformed}$ urinary arsenic (creatinine adjusted) ($p < 1.3 \times 10^{- 7}$). Meta-analysis was conducted using the METAL software, and summary statistics from the covariate- and surrogate variable (SV)--adjusted models for HEALS and BEST were provided as input. Direction of association indicated by arrows for HEALS and BEST, and downward and upward arrows correspond to inverse and positive association with increasing arsenic exposure. UCSC gene annotation provided by Illumina. BEST, Bangladesh Vitamin E and Selenium Trial; Chr, chromosome; HEALS, Health Effects of Arsenic Longitudinal Study.

Among the BEST participants, gene expression data was available for 26 of the 28 genes that annotated to our urinary arsenic--associated CpGs ($p < 1.3 \times 10^{- 7}$) (Table S5). At a threshold of $p = 0.05$, methylation was positively correlated with gene expression for four genes: *RNF144A* (ring finger protein 144A) (cg19240637; $p = 1.9 \times 10^{- 5}$), *C19orf66* (cg13480898; $p = 1.6 \times 10^{- 3}$), *SEMA5B* (semaphorin 5B) (cg02306995; $p = 0.035$), and *NELF* (negative elongation factor) (cg04622454; $p = 0.031$). Inverse correlations between methylation and expression were observed for five CpGs in four genes: *EML2* (cg06381803; $p = 0.039$), *FCER2* (Fc fragment of IgE receptor II) (cg12261095; $p = 0.010$), *B3GALT5* (beta-1,3-galactosyltransferase 5) (cg26390598; $p = 0.035$), and *LCN8* (lipocalin 8) (cg14145338; $p = 7.0 \times 10^{- 4}$ and cg13764516; $p = 6.4 \times 10^{- 3}$). After adjustment for age and sex, six of the nine associations between expression and methylation persisted ($p < 0.05$). Among the HEALS participants, genotyping information was available for 389 participants, and we examined whether the top arsenic-associated CpGs identified in the meta-analysis ($n = 41$) were associated with genetic variants (within 1 megabase window) (Table S6). Twenty-five out of the 41 arsenic-associated CpGs had one or more cis-mQTL pairs ($\text{FDR} < 0.01$), suggesting that these CpGs and the genetic variants that influence their methylation status could be further explored in gene environment studies.

We attempted replication of the arsenic-associated CpGs identified in this meta-analysis in a group of Andean women from Argentina, who were exposed to arsenic via drinking water, ($n = 93$) with DNA methylation measured on the $450K$ array, as previously described by Ameer et al. ([@c4]). Among the arsenic-associated CpGs from the meta-analysis ($n = 217$), only 16 CpGs were associated with urinary arsenic ($p < 0.05$) among the Andean women and 13 (81.3%) with consistent direction of association (Excel Table S4). While these results suggest some consistency among the arsenic-associated CpGs identified in our study, there is heterogeneity with respect to study population, sample size, study design, and analysis approach.

Enrichment of Arsenic-Associated CpGs (from Meta-Analysis) in Genomic Features and Gene Sets {#s3.6}
--------------------------------------------------------------------------------------------

Similar to our discovery analysis in HEALS using the EPIC array, we examined enrichment of genomic features among the urinary arsenic--associated CpGs identified in the meta-analysis. Arsenic-associated CpGs identified in the meta-analysis were enriched in shores and non-CpG islands and depleted in islands compared with CpGs not associated with arsenic ($p = 7.9 \times 10^{- 8}$) ([Figure 5A](#f5){ref-type="fig"}). Arsenic-associated CpGs were depleted in promoters ($p = 1.1 \times 10^{- 3}$) and enriched in DHS regions ($p = 2.2 \times 10^{- 7}$) ([Figure 5B](#f5){ref-type="fig"}). Notably, arsenic-associated CpGs were 2.6-fold more likely to be located within enhancers compared with CpGs not associated with arsenic ($p = 1.2 \times 10^{- 3}$). When we stratified by the direction of association, the genomic enrichment in DHS regions and enhancers and depletion in promoters persisted among negatively arsenic-associated CpGs (see Figure S8).

GSEA was applied to the urinary arsenic--associated CpGs identified in the meta-analysis among the associated CpGs with FDR of 0.05 (153 unique genes) and among the top 500 arsenic-associated CpGs (338 unique genes). Among both sets of arsenic-associated CpGs, we observed enrichment of genes annotating to the $\text{PI}_{3}K/\text{AKT}/\text{mTOR}$, allograft rejection, reactive oxygen species pathway, inflammatory response, and $\text{TNF}\alpha$ signaling via $\text{NF}\kappa B$ hallmarks ($p < 0.05$) ([Table 3](#t3){ref-type="table"}). We observed enrichment of 13 KEGG pathways among the arsenic-associated CpGs with FDR of 0.05 (Table S4). Among the top 500 arsenic-associated CpGs, genes in this set annotated to KEGG pathways related to cell adhesion molecules (CAMs) (nine genes; $p = 2.9 \times 10^{- 3}$), mitogen-activated protein kinase signaling pathway (14 genes; $p = 0.013$), estrogen signaling pathway (eight genes; $p = 0.015$), hematopoietic cell lineage (four genes; $p = 0.038$), cysteine and methionine metabolism (three genes; $p = 0.048$), and $\text{NF}\kappa B$ signaling pathway (five genes; $p = 0.029$).

Discussion {#s4}
==========

This EWAS of arsenic exposure provides evidence that arsenic exposure is associated with DNA methylation levels at specific CpG sites in the leukocytes of Bangladeshi adults. In our discovery analysis, we identified 34 novel CpGs associated with arsenic exposure assessed in urine in HEALS prior to any arsenic mitigation efforts. Sixteen of these novel arsenic-associated CpGs were also present on the $450\; K$ array, and ten replicated in an independent cohort (BEST). For the 34 novel arsenic-associated CpGs observed in HEALS, results for arsenic exposure measured in drinking water were highly consistent with results based on urinary arsenic. Our meta-analysis of HEALS and BEST identified 221 CpGs associated with arsenic exposure assessed in urine in Bangladeshi adults. Arsenic-associated CpGs were more likely to be hypomethylated and were enriched in CpG shores, DHS regions, and enhancers.

Our results are relevant to understanding how arsenic impacts the epigenome and how alteration of the epigenome may be a mechanism involved in arsenic toxicity. Among our top CpGs from both the discovery analysis and meta-analysis, we observed that higher arsenic exposure tends to be associated with hypomethylation, a phenomenon not observed in prior studies ([@c4]; [@c8]; [@c50]; [@c75]), potentially due to the increased coverage of the EPIC array of intergenic and non-promoter regulatory genomic regions compared with the $450\; K$ array. While the prior adult EWAS of arsenic exposure identified more CpGs associated with hypermethylation than hypomethylation ([@c8]; [@c50]), arsenic exposure was associated with decreased global methylation, assessed using the $\left\lbrack {3H} \right\rbrack\text{-methyl}$ incorporation assay in Bangladeshi adults ([@c60]). In addition, methylation is more variable in CpG shores and may be more susceptible to changes due to environmental exposures such as arsenic ([@c38]). While the location of arsenic-associated CpG methylation in relation to CpG islands needs to be further studied, arsenic-associated CpGs were enriched in CpG shores in the cord blood from low-exposed infants ([@c44]) and in non-CpG island regions in the umbilical artery and placenta from Bangladeshi infants ([@c16]). A meta-analysis of maternal smoking and genome-wide methylation in cord blood observed similar enrichment in CpG shores and within enhancers and DHS regions and depletion in CpG islands and promoter regions ([@c39]).

While the mechanisms for alteration of DNA methylation in blood by arsenic remains to elucidated, two proposed mechanisms involve the influence of arsenic: *a*) on the expression or function of DNA methyltransferases, potentially resulting in less downstream site-specific methylation; or *b*) on consumption of methyl groups during arsenic metabolism, resulting in depletion of methyl groups available to DNA methyltransferase, affecting DNA methylation synthesis ([@c25]). In addition, it is possible that specific genes are expressed in response to arsenic exposure, and the induction of these genes may change the local epigenetic state, including DNA methylation. Arsenic-associated methylation in DHS regions and enhancers warrants further exploration in both experimental and genome-wide methylation studies.

In our discovery and replication analysis, two of the top CpGs were located upstream of the ABR gene, encoding the active BCR-related protein. ABR is a regulator of the RHO family of small GTPases, signaling proteins involved in cytosketal dynamics, and a paralog of the *BCR* (BCR activator of RhoGEF and GTPase) gene. ABR has a GTPase-activating protein domain and may be important in cellular signaling and immune processes ([@c20]; [@c21]; [@c23]). In addition, ABR may have a pivotal role in human embryonic stem cell mitosis, suggesting that ABR may be important for maintaining the genomic integrity and renewal of stem cells ([@c62]). A study of newborns ($n = 38$) in the Biomarkers of Exposure to Arsenic (BEAR) pregnancy cohort from Mexico identified two CpGs also negatively associated with maternal water arsenic in the *ABR* gene body ([@c71]). Arsenic increased *ABR* expression in an *in vitro* study of arsenic exposure in human epidermal keratinocytes ([@c63]). No prior methylation or experimental evidence has been identified for the other discovered urinary arsenic--associated CpGs.

Among the arsenic-associated CpGs from our meta-analysis, we observed some consistency with prior EWAS and gene expression studies of arsenic exposure. In the BEAR pregnancy cohort of Mexican infants, arsenic exposure was associated with methylation at CpGs within the following genes that also annotated to CpGs identified in our meta-analysis: *TBC1D24* (TBC1 domain family member 24), *ERC2*, and *PRRC2A* (proline rich coiled-coil 2A) ([@c71]). TBC1D24 is a protein that is hypothesized to be involved in vesicle transport and oxidative stress response. The *PRRC2A* gene is within the vicinity of the $\text{TNF\ -}\alpha$ and $\text{TNF\ -}\beta$ encoding regions and may be involved in inflammatory response. In a cohort of Bangladeshi infants, methylation in the first exon of *ERC2* was differentially methylated with maternal water arsenic ([@c42]). Maternal arsenic exposure increased EML2 protein levels in the cord blood of infants from the BEAR cohort ([@c13]). *In vitro* arsenic exposure increased *SQSTM1* and *UNKL* expression and decreased SPSB1 transcript stability in human fibroblasts ([@c68]) and increased *MCC* (mutated in colorectal cancer) expression in human epidermal keratinocytes ([@c63]). The S*QSTM1* encodes a protein that is involved in selective autophagy and cell senescence and is within the $\text{TNF\ -}\alpha$ inflammatory response pathway. In Excel Table S5, we identified arsenic-associated CpGs from the prior literature and reported the replication results from HEALS and our meta-analysis.

There was no overlap between our identified arsenic-associated CpGs and metal-associated CpGs reported in prior studies of *in utero* exposure to mercury ([@c17]), lead ([@c74]), and cadmium ([@c43]; [@c56]; [@c73]). A meta-analysis of *in utero* cadmium exposure identified a differentially methylated CpG (cg16768966) within *GAS7*, encoding growth arrest protein 7, and arsenic was also associated with methylation at this same gene but not the same CpG ([@c26]). Overall, this lack of overlap between arsenic-associated CpGs and CpGs associated with other metals suggests that arsenic may have a toxicant specific effect on the epigenome.

GSEA enabled us to identify pathways potentially affected by arsenic-associated DNA methylation alterations in whole blood. Our arsenic-associated CpGs annotated to genes in hallmark gene sets related to reactive oxygen species, cancer and aging, and inflammatory response pathways, specifically $\text{TNF\ -}\alpha$ signaling via $\text{NF}\kappa B$. Arsenic primarily undergoes biotransformation via methylation by AS3MT but may also involve glutathione conjugation and other antioxidant and xenobiotic metabolizing enzymes ([@c37]). Arsenic exposure also induces expression of numerous proteins involved in $\text{NF}\kappa B$ response, $\text{TNF\ -}\alpha$ signaling, and inflammation in exposed infants and children ([@c13]; [@c28]; [@c77]) and adults ([@c24]). The KEGG pathway for CAMs also has been identified as enriched in a study of Bangladeshi infants ([@c42]) and low-exposed U.S. adults ([@c50]). CAMs are universally important in hemostasis, immune response, and development. Among a subset of BEST participants, baseline arsenic exposure was associated with increased circulating CAMs at baseline and an increase in CAMs between baseline and 6-month follow-up ([@c18]). In a study of Bangladeshi infants, arsenic-associated CpGs were also enriched in KEGG pathways, including hematopoietic cell lineage, calcium signaling pathway, Notch signaling, and mTOR signaling ([@c42]). While there is heterogeneity in GSEA approaches, the results from our GSEA and prior EWAS suggest some associations between arsenic exposure and DNA methylation may be consistent across different stages of development and exposure levels. Within the GWAS Catalog (<https://www.ebi.ac.uk/gwas/>), several variants within or near genes that annotated to the arsenic-associated CpGs were associated with a broad range of health traits with potential connections to arsenic exposure. These health traits included many types of cancer, lymphocyte and red blood cell phenotypes and composition, pulmonary function, and blood pressure (Table S7), suggesting that genetic variation and potentially epigenetic variation in these genes may contribute to the risk of arsenic-associated disease and health traits.

A major strength of our study was the large sample size, with $\sim 400$ individuals in both the discovery and replication datasets, resulting in 796 arsenic-exposed adults for meta-analysis. Utilizing methylation data from BEST, we were able to conduct replication analyses, enabling us to validate discovered associations between urinary arsenic and CpG methylation. Our meta-analysis increased the power to detect putative arsenic-associated CpGs that can be examined in future studies. The EPIC array measures methylation at almost twice the number of CpGs compared with the $450\; K$ array used in prior studies and improves coverage within intergenic regions, enhancers, and distal regulatory elements ([@c66]). In HEALS, water and urinary arsenic were assessed at baseline prior to interventions to remediate exposure; thus, these measures are likely to represent historical exposure status, allowing us to potentially identify CpGs associated with long-term exposure, as opposed to more acute responses to exposure. The exposure range in both HEALS and BEST participants was wide, enabling us to evaluate a broad spectrum of environmental arsenic exposure and its effect on genome-wide methylation.

Several limitations must be considered when interpreting the results of our study. While urinary arsenic is the most common biomarker of recent arsenic exposure, sampling and interindividual factors, such as age, sex, and metabolism, can contribute to variation in urinary arsenic measurements ([@c51]). Unmeasured confounding, from unknown biologic and technical variation, and measurement error can also potentially bias our results. DNA methylation was measured in whole blood, and the associations we observed in blood may not be present in other tissues. The EPIC array measures methylation at $\sim 3\%$ of CpGs in the genome ([@c78]) and is biased toward gene regions, and DMR analysis preferentially identifies DMRs in gene regions since intergenic CpGs are more sparsely distributed on the array ([@c64]). We currently cannot replicate results for CpGs specific to the EPIC array. The association between gene expression and methylation (measured on EPIC) cannot be assessed in HEALS since RNA is not available. Genetic background can influence DNA methylation, and the arsenic--CpG associations observed in this work may not be present in other arsenic-exposed populations due to genetic differences ([@c14]; [@c55]). Even among our significant arsenic-associated CpGs, the effect sizes of the associations between arsenic and DNA methylation at CpGs are small, and it is unknown whether these small effects have functional consequences.

Future studies using the EPIC array (or more comprehensive measurement technologies) will be necessary to confirm the novel CpGs we identified and the enrichment of arsenic-associated CpGs among CpG shores and enhancers. Other factors, such as individual genetic susceptibility to arsenic exposure and timing and duration of arsenic exposure, need to be explored in studies of arsenic-associated methylation. While the EPIC array enables us to study the effect of arsenic on genic regions, we still do not know how arsenic affects global methylation, and bisulfite genomic sequencing approaches are needed to understand the effect of arsenic on the global epigenome, especially in intergenic regions. The relationship between arsenic-related variation in DNA methylation and local histone and chromatin features require further study, and these features likely have important implications for regulation of arsenic response genes as well as arsenic toxicity and disease risk. Finally, arsenic-associated CpGs identified here and elsewhere should be explored as potential biomarkers of arsenic exposure, susceptibility, and toxicity. Because some of the arsenic-associated CpGs identified in our analysis annotate to important inflammatory, oxidative response, and other cell regulation pathways, alterations in DNA methylation may be important biologic responses and/or markers of arsenic exposure that may better inform our understanding of and predict arsenic-associated health effects and disease.

Conclusions {#s5}
===========

Among Bangladeshi adults chronically exposed to arsenic via drinking contaminated water from tube wells, we identified novel and reproducible arsenic-associated DNA methylation alterations in blood. Our meta-analysis that combines our results with a prior study identified additional CpGs showing a putative association with arsenic exposure. Arsenic-associated CpGs annotated to genes involved in $\text{TNF}\alpha$ signaling via $\text{NF}\kappa B$, CAMs, inflammatory processes, and important signaling pathways in cancer and aging. The implications of these arsenic-associated CpGs for exposure and risk assessment and potential toxicity prevention should be further investigated.
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